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A bs tr ac t
Background
Data regarding health outcomes among living kidney donors are lacking, especially 
among nonwhite persons.
Methods
We linked identifiers from the Organ Procurement and Transplantation Network 
(OPTN) with administrative data of a private U.S. health insurer and performed a 
retrospective study of 4650 persons who had been living kidney donors from Octo-
ber 1987 through July 2007 and who had post-donation nephrectomy benefits with 
this insurer at some point from 2000 through 2007. We ascertained post-nephrec-
tomy medical diagnoses and conditions requiring medical treatment from billing 
claims. Cox regression analyses with left and right censoring to account for observed 
periods of insurance benefits were used to estimate absolute prevalence and preva-
lence ratios for diagnoses after nephrectomy. We then compared prevalence pat-
terns with those in the 2005–2006 National Health and Nutrition Examination 
Survey (NHANES) for the general population.
Results
Among the donors, 76.3% were white, 13.1% black, 8.2% Hispanic, and 2.4% an-
other race or ethnic group. The median time from donation to the end of insurance 
benefits was 7.7 years. After kidney donation, black donors, as compared with white 
donors, had an increased risk of hypertension (adjusted hazard ratio, 1.52; 95% 
confidence interval [CI], 1.23 to 1.88), diabetes mellitus requiring drug therapy 
(adjusted hazard ratio, 2.31; 95% CI, 1.33 to 3.98), and chronic kidney disease (ad-
justed hazard ratio, 2.32; 95% CI, 1.48 to 3.62); findings were similar for Hispanic 
donors. The absolute prevalence of diabetes among all donors did not exceed that 
in the general population, but the prevalence of hypertension exceeded NHANES 
estimates in some subgroups. End-stage renal disease was identified in less than 1% 
of donors but was more common among black donors than among white donors.
Conclusions
As in the general U.S. population, racial disparities in medical conditions occur 
among living kidney donors. Increased attention to health outcomes among demo-
graphically diverse kidney donors is needed. (Funded by the National Institute of 
Diabetes and Digestive and Kidney Diseases and others.)
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Living kidney transplantation is considered to offer patients with end-stage renal disease the best opportunity for dialy-
sis-free survival.1 In 2006, approximately 27,000 
transplantations from registered living kidney 
donors were performed worldwide,2 and living 
donors supplied nearly 40% of kidney transplants 
in the United States.3 Most evidence concerning 
the safety of living kidney donation for donors 
derives from single-center studies with limited 
statistical power and few nonwhite donors.4 In a 
recent study, investigators at the University of 
Minnesota achieved high ascertainment of long-
term patient and renal survival and reported no 
adverse effects of living kidney donation on life 
span or risk of end-stage renal disease, as com-
pared with survey data from the general U.S. 
population.5 Notably, in the Minnesota cohort, 
98.8% of the patients were white.
Linkage of records from the Organ Procure-
ment and Transplantation Network (OPTN) (as 
supplied by the United Network for Organ Shar-
ing) with the Social Security Administration’s 
Death Master File recently indicated that although 
surgical and long-term mortality were higher 
among black donors than among white donors, 
the long-term rate of death did not exceed that 
of corresponding control subjects in the National 
Health and Nutrition Evaluation Survey (NHANES).6 
Although racial disparities in the burden and con-
sequences of diabetes mellitus, hypertension, and 
chronic kidney disease in the general population 
have been extensively documented,7-10 few data 
exist concerning long-term medical outcomes 
among nonwhite kidney donors.
Currently, the OPTN collects data on living 
donors for only 2 years of follow-up,11 and incom-
plete reporting and donor loss to follow-up are 
common,12 owing in part to compliance barriers, 
such as cost and inconvenience.13 Thus, addition-
al methods for capturing health outcomes among 
racially diverse living kidney donors are needed. 
To determine longer-term postdonation medical 
outcomes independent of a donor’s interaction 
with the transplantation center, we linked admin-
istrative data from a private insurance provider 
with OPTN-supplied identifiers for living donors. 
Using these data, we identified postdonation 
diagnoses of hypertension, diabetes mellitus, 
chronic kidney disease, and cardiovascular dis-
ease; investigated variation in the risk of post-
donation medical diagnoses, according to socio-
demographic traits; and estimated the prevalence 
of these diagnoses in demographic subgroups. We 
also compared relative and absolute prevalence 
estimates with those in recent NHANES data.
Me thods
Data Sources and Participant Selection
We assembled our study data by linking OPTN 
records for living kidney donors with administra-
tive data from a national private U.S. health in-
surer. OPTN data include information on all do-
nors and transplant recipients in the United States, 
as submitted by OPTN members.14 The Health 
Resources and Services Administration (HRSA) 
provides oversight on the activities of the OPTN. 
After approval by the institutional review board 
at Saint Louis University, we linked beneficiary 
identifier numbers from the insurer’s electronic 
databases, using names and birthdates, with 
unique OPTN identifiers for living kidney donors. 
Analyses were performed with the use of limited 
data sets in compliance with the provisions of 
the Health Insurance Portability and Account-
ability Act with all direct identifiers removed.
Study participants were eligible if they had an 
OPTN record of having served as a living kidney 
donor from October 1987 through July 2007 and 
were eligible for benefits under the participating 
insurer after donor nephrectomy at some point 
during the period from May 2000 through De-
cember 2007, the period of available claims data. 
All participants were simultaneously enrolled in 
medical and pharmacy benefits with this com-
pany exclusively during the study window. U.S. 
Census data were incorporated according to 
residential ZIP Code at the time of donor neph-
rectomy.
Outcome Measures
We ascertained medical diagnoses of hyperten-
sion, diabetes mellitus, chronic kidney disease, 
and cardiovascular disease among living kidney 
donors, using billing claims with corresponding 
diagnosis codes as listed in the International Classi-
fication of Diseases, Ninth Revision, Clinical Modifica-
tion, similar to algorithms described previously.15-19 
We also examined drug-treated hypertension and 
diabetes (with either insulin or oral agents) in 
pharmacy claims, using drug-category codes. 
Stage-specific coding for chronic kidney disease 
was introduced in October 2005. Therefore, we 
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examined diagnoses of chronic kidney disease 
of stage 3 to 5 or end-stage renal disease (i.e., 
chronic kidney disease requiring dialysis) in a 
prespecified subgroup with insurance eligibility 
ending June 2006 or later.
Baseline Demographic Variables
Demographic data from the OPTN at the time of 
donor nephrectomy included age, sex, and race 
or ethnic group, as reported by the donor to the 
transplantation center. Because the OPTN began 
collecting information on predonation hyperten-
sion in June 2004, we examined baseline hyper-
tension status in a secondary analysis. An index 
of neighborhood socioeconomic status at the time 
of nephrectomy was computed from U.S. Census 
data linked by ZIP Code, according to methods 
used by the Agency for Healthcare Research and 
Quality20 (for details, see the Methods section in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org).
Comparison Data for the General Population
Information about race is not recorded by the in-
surer and was unavailable for nondonor benefi-
ciaries. Thus, we compared our results with those 
of population-based survey data from NHANES,21 
as has been done in other studies of donor out-
comes.5,6 We included participants in the 2005–
2006 NHANES survey who were 20 years of age 
or older. Race or ethnic group in NHANES was 
self-reported. Hypertension, diabetes, chronic kid-
ney disease, and cardiovascular disease were de-
fined according to the participant’s report of these 
diagnoses on the basis of encounters with a doc-
tor or other health care professional.
Statistical Analysis
Data sets were merged and analyzed with the use 
of SAS for Windows software, version 9.2 (SAS 
Institute). Since windows of insurance benefits 
varied across the sample, we used Cox regression 
with left and right censoring to account for ob-
served periods of insurance benefits to model the 
frequency with 95% confidence intervals and cor-
relates with adjusted hazards ratios of prevalent 
diagnoses after donor nephrectomy (Fig. 1). The 
prevalence of diagnoses 5 years after donor ne-
phrectomy in the full cohort and in prespecified 
subgroups was estimated from outcome-specific 
Cox models. We estimated correlates of prevalent 
diagnoses in the general population using SAS 
Proc Survey logistic software to correct for un-
equal selection probabilities and response rates 
in NHANES. The prevalence of medical condi-
tions in subgroups in the general population was 
estimated by transforming the logistic-regression 
equation. A P value of less than 0.05 was consid-
ered to indicate statistical significance.
R esult s
Demographic Characteristics of Donors
Among 4650 kidney donors in the study cohort, 
76.3% were white, 13.1% black, 8.2% Hispanic, 
and 2.4% another race or ethnic group (Table 1). 
White donors were significantly older at the time 
of donation than were nonwhite donors in the 
study sample and nationally (P<0.001 by analysis 
of variance). All kidney donors underwent neph-
rectomy between 1987 and 2007, and the median 
time from donation to the end of observed insur-
ance eligibility was 7.7 years. The linked donor 
sample was similar on the basis of race and sex 
to all living kidney donors in the OPTN and to 
age-standardized estimates in the general popu-
lation in NHANES.
Frequency and Variation of Medical 
Diagnoses
At 5 years after donation, the estimated preva-
lence of diagnosed hypertension was 17.8% (95% 
confidence interval [CI], 15.8 to 20.2), and the 
estimated prevalence of drug-treated hyperten-
sion was 13.6% (95% CI, 11.4 to 15.8). Diagnoses 
of diabetes and cardiovascular disease were iden-
Donor nephrectomy,
OPTN registry data,
U.S. Census data Window of insurance benefits,
claims data with diagnoses
Left censoring Right censoring
Figure 1. Schematic Diagram of Linkage of Study Data Sources.
Identifiers from the Organ Procurement and Transplantation Network 
(OPTN) were linked to the administrative data of a private U.S. health in-
surer for 4650 living kidney donors from October 1987 through July 2007. 
Post-nephrectomy medical diagnoses and conditions requiring medical 
treatment were ascertained from billing claims. Cox regression analyses 
with left and right censoring to account for observed periods of insurance 
benefits were used to estimate absolute prevalence and prevalence ratios 
for diagnoses after nephrectomy. Prevalence patterns were then compared 
with those in the 2005–2006 National Health and Nutrition Examination 
Survey (NHANES) for the general population. U.S. Census data were incor-
porated according to residential ZIP Code at the time of donor nephrectomy.
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tified in 4.0% (95% CI, 2.7 to 5.3) and 3.2% (95% 
CI, 2.1 to 4.2) of donors, respectively. Chronic 
kidney disease was indicated as a medical diag-
nosis in the claims of 5.2% (95% CI, 3.7 to 6.8) 
of donors by the fifth anniversary of donation.
Older age at donation was associated with an 
increased risk of postdonation hypertension of 
6% per year (Table 2). As compared with white 
kidney donors, black donors had a relative in-
crease of 52% in the risk of diagnosed hyperten-
sion and an increase of 31% in the risk of drug-
treated hypertension. The risk of diagnosed 
hypertension was 36% higher among Hispanic 
donors than among white donors, although the 
risk of drug-treated hypertension did not differ 
significantly between the two groups. Baseline 
hypertension was reported in 12 of 399 donors 
(3.0%) from June 2004 through 2007; of these 
patients, 11 were white, and 1 was Hispanic. 
Among donors after nephrectomy, reported pre-
donation hypertension was strongly correlated 
with an increased risk of hypertension (adjusted 
hazard ratio, 12.2; 95% CI, 5.6 to 26.7) and with 
drug treatment for hypertension (adjusted hazard 
ratio, 20.9; 95% CI, 8.8 to 49.3). However, the 
inclusion of this variable did not have a signifi-
cant effect on the association between black race 
or Hispanic ethnic background with hypertension 
or black race with drug-treated hypertension 
after donor nephrectomy. In NHANES data, black 
respondents reported receiving a diagnosis of 
hypertension more commonly than did white re-
spondents, whereas Hispanic respondents were 
less likely than white respondents to report diag-
nosed hypertension.
The relative frequency of diagnosed diabetes 
among donors rose 5% for each increase in year 
of age at the time of donation (Table 2). There 
were borderline trends toward more frequent di-
agnoses of diabetes after donation among black 
and Hispanic donors than among white donors 
(P = 0.05 for both comparisons). Black and His-
panic donors were more than two times as likely 
as white donors to have drug-treated diabetes 
after kidney donation. In NHANES data, reported 
diabetes was more than twice as common among 
black and Hispanic respondents as among white 
respondents.
The relative risk of medically coded chronic 
kidney disease after donation increased 4% per 
Table 1. Demographic Characteristics of Living Kidney Donors in the Study Sample and in the Organ Procurement  
and Transplantation Network (OPTN), 1987–2007.*
Characteristic
Living Donors 





Male sex (%) 45.4 42.2
Race or ethnic group (%)†
Non-Hispanic white 76.3 70.9
Non-Hispanic black 13.1 13.1
Hispanic 8.2 11.8
Other 2.4 4.3
Related to recipient (%) 81.2 74.4
Age at donor nephrectomy (yr)
All donors 37.2±10.0 39.3±10.9
Non-Hispanic white 38.2±10.0 40.7±10.9
Non-Hispanic black 33.9±9.0 35.5±9.9
Hispanic 34.3±9.6 35.9±10.4
Other 34.8±10.8 38.1±11.3
Median time from donation to end of insurance eligibility (yr) 7.7 NA
Median duration of insurance eligibility (yr) 2.1 NA
* Plus–minus values are means ±SD. After adjustment for the sampling technique used in the 2005–2006 National 
Health and Nutrition Examination Survey (NHANES), 48.1% of respondents represented in the general population 
were men, 71.7% were non-Hispanic white, 11.5% were non-Hispanic black, 8.0% were Hispanic of Mexican ancestry, 
and 8.8% were another race or ethnic group. NA denotes not applicable.
† Race or ethnic group was self-reported.
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year of age at the time of donation (Table 2). 
Black and Hispanic donors were approximately 
twice as likely to have diagnosed chronic kidney 
disease after nephrectomy as were white donors. 
Prespecified subgroup analysis of 2307 donors 
who had medical benefits after the introduction 
of stage-specific coding for chronic kidney dis-
ease showed that donors had a significant in-
crease in the risk of chronic kidney disease of 
stage 3 or higher if they were black (adjusted 
hazard ratio, 3.60; 95% CI, 1.37 to 9.39; P = 0.009) 
or Hispanic (adjusted hazard ratio, 4.23; 95% CI, 
1.52 to 11.75; P = 0.006). Chronic kidney disease 
requiring dialysis (i.e., end-stage renal disease) 
was reported in 2 of 271 black donors (0.7%) and 
1 of 197 Hispanic donors (0.5%) in this sub-
analysis, as compared with no cases among 1786 
white donors (P = 0.02 by Fisher’s exact test for 
the comparison between black and white donors 
and P = 0.10 for the comparison between Hispan-
ic and white donors). The time from donation to 
end-stage renal disease ranged from 6.3 to 16.5 
years. In NHANES, the relative risk of chronic 
kidney disease in black respondents was twice 
that in white respondents.
Although reported cardiovascular disease was 
significantly more common among black respon-
dents than among white respondents in the gen-
eral population, we did not detect racial variation 
in the prevalence of cardiovascular diagnoses 
among kidney donors.
At 5 years after nephrectomy, the prevalence 
of diagnosed hypertension varied from 13.9% 
among white women who were 35 years of age 
at the time of donation to 47.9% among black 
men who were 50 years of age at the time of 
donation (Table 3). At the same time, the preva-
lence of diagnosed diabetes varied from 3.2% in 
white men who were 35 years of age at the time 
of donation to 10.8% in Hispanic women who 
were 50 years of age at the time of donation. The 
point estimates for the prevalence of diabetes 
among black and Hispanic donors were lower 
than those in the general population, but the es-
timated prevalence of hypertension among His-
panic donors was higher than that in the general 
population. There was a trend toward increased 
point estimates for the prevalence of hyperten-
sion, as compared with the general population, 
among black male and female donors and white 
male donors who were 50 years of age at the 
time of donation, but confidence intervals over-
lapped those of NHANES.
Race, Socioeconomic Indicators, and Medical 
Outcomes after Kidney Donation
Census data were linked for 3385 donors (72.8%) 
in our study. In this group, the index of socioeco-
Table 2. Adjusted Relative Risk of Hypertension, Diabetes, Chronic Kidney Disease, and Cardiovascular Disease in Living Kidney Donors  
and in the General Population, According to Demographic Factors.*
Variable Hypertension Diabetes
Living Donors† NHANES‡ Living Donors† NHANES‡
Medical Claims Drug-Treated Reported Medical Claims Drug-Treated Reported
adjusted hazard ratio  
(95% CI)
adjusted odds ratio 
(95% CI)
adjusted hazard ratio  
(95% CI)
adjusted odds ratio 
(95% CI)
Age (per year) 1.06 (1.06–1.07)§ 1.06 (1.05–1.07)§ 1.06 (1.05–1.07)§ 1.05 (1.03–1.06)§ 1.05 (1.03–1.07)§ 1.05 (1.04–1.06)§
Male sex 1.13 (0.98–1.31) 1.21 (1.03–1.43)§ 0.93 (0.82–1.07) 0.91 (0.68–1.22) 1.10 (0.73–1.66) 0.96 (0.71–1.31)
Race or ethnic group
Non-Hispanic white Reference Reference Reference Reference Reference Reference
Non-Hispanic black 1.52 (1.23–1.88)§ 1.31 (1.02–1.68)§ 1.77 (1.47–2.14)§ 1.52 (1.00–2.30)¶ 2.31 (1.33–3.98)§ 2.74 (2.13–3.51)§
Hispanic 1.36 (1.04–1.78)§ 1.03 (0.73–1.46) 0.65 (0.51–0.83)§ 1.65 (1.00–2.74)¶ 2.94 (1.57–5.51)§ 2.34 (1.76–3.12)§
Other 1.13 (0.68–1.85) 0.48 (0.20–1.16) 0.85 (0.66–1.10) 1.35 (0.50–3.67) 2.58 (0.80–8.28) 2.47 (1.52–1.40)§
* Cardiovascular disease is defined as coronary artery disease, angina, congestive heart failure, heart attack, or stroke. CI denotes confidence interval.
† Adjusted hazard ratios for medical diagnoses among donors were calculated by means of multivariate Cox regression with left and right 
censoring to account for observed periods of insurance benefits.
‡ Adjusted odds ratios for patient-reported diagnoses in the National Health and Nutrition Examination Survey (NHANES) were calculated by 
means of multivariable logistic regression with correction for unequal selection probabilities and response rates.
§ P<0.05.
¶ P = 0.05.
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nomic indicators was significantly less favorable 
among black and Hispanic donors than among 
white donors (Table 4). However, socioeconomic 
indicators were not associated with any study out-
come in bivariate or multivariate analyses. For ex-
ample, an increased score on the socioeconomic 
index was not associated with a significant dif-
ference in the risk of hypertension (hazard ratio, 
1.00; 95% CI, 0.99 to 1.02), diabetes (hazard ra-
tio, 0.99; 95% CI, 0.93 to 1.02), or chronic kidney 
disease (hazard ratio, 0.97; 95% CI, 0.92 to 1.01).
Discussion
Long-term health outcomes have not been well 
defined among racially diverse living kidney do-
nors. We used administrative insurance data that 
were collected in the course of actual practice to 
examine medical diagnoses among living kidney 
donors, independent of follow-up by the trans-
plantation center. As compared with white donors, 
black and Hispanic donors had an increased risk 
of hypertension, drug-treated diabetes, and chron-
ic kidney disease after nephrectomy than did 
white donors, increases that were not explained 
by socioeconomic factors. The absolute prevalence 
of diabetes in donors did not exceed that in the 
general population, but the prevalence of hyper-
tension was higher than NHANES estimates in 
some subgroups. End-stage renal disease was re-
ported in less than 1% of donors but was more 
common among black donors than among white 
donors. Thus, as in the general U.S. population,7-10 
racial disparities in medical conditions appear to 
occur among kidney donors.
We found that black donors had an increased 
risk of hypertension, as compared with white 
donors, similar to racial disparities in the gener-
al population. The Amsterdam Forum’s medical 
guidelines for living kidney donors state that the 
presence of hypertension at the time of evalua-
tion is a general exclusion to kidney donation, 
except in patients with hypertension whose con-
dition is defined as “low risk.”22 According to the 
seminal Mayo Clinic study,23 white race is in-
cluded among low-risk criteria. Recent data from 
predominantly white cohorts suggest that there 
is an increased risk of hypertension among do-
nors, as compared with the general population, 
possibly due to physiological alterations (includ-
ing hyperfiltration in the remaining kidney and 
changes in vascular tone and renin–angiotensin–
aldosterone regulation) or heightened follow-
up.24,25 Hypertension was recently identified in 
41% of 39 black donors who were evaluated at an 
average of 7 years after nephrectomy at one cen-
ter.26 In our study, the increased prevalence of 
hypertension among Hispanic donors, as com-
pared with the general population, may, in part, 
reflect underreporting of hypertension in this 
ethnic group, as compared with white respon-
dents, in NHANES. Other studies have reported 
decreased rates of hypertension among Hispanic 
persons, as compared with non-Hispanic white 
persons, on the basis of both self-reporting and 
measured blood pressure.8,27-30 Nonetheless, in 
our study, the prevalence of hypertension among 
Hispanic donors did not exceed that among 
black donors. We speculate that medical surveil-
lance after kidney donation may mitigate barriers 
Chronic Kidney Disease Cardiovascular Disease
Living Donors† NHANES‡ Living Donors† NHANES‡
Medical Claims Reported Medical Claims Reported
adjusted hazard ratio 
(95% CI)
adjusted odds ratio 
(95% CI)
adjusted hazard ratio 
(95% CI)
adjusted odds ratio 
(95% CI)
1.04 (1.03–1.06)§ 1.02 (1.01–1.03)§ 1.09 (1.07–1.19)§ 1.08 (1.07–1.09)§
1.64 (1.16–2.34)§ 0.59 (0.42–0.84)§ 2.11 (1.43–3.10)§ 1.43 (1.10–1.87)§
Reference Reference Reference Reference
2.32 (1.48–3.62)§ 1.98 (1.34–2.94)§ 1.15 (0.63–2.11) 1.44 (1.11–1.88)§
1.90 (1.05–3.43)§ 1.42 (0.88–2.27) 0.91 (0.37–2.26) 1.04 (0.71–1.52)
1.74 (0.66–4.76) 0.95 (0.31–2.96) 0.49 (0.07–3.54) 0.86 (0.45–1.67)
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to the recognition of hypertension rather than 
differentially affect the risk of hypertension 
among Hispanic donors.
As in the general population, diabetes was 
more common among black and Hispanic donors, 
as compared with white donors. Canadian re-
searchers recently found a substantially higher 
risk of diabetes after kidney donation among 
aboriginal donors than among white donors, 
mirroring the disparities in risk in the local 
population.31 However, in our study, the estimat-
ed prevalence of diabetes among black or His-
panic donors did not exceed the prevalence 
among corresponding subgroups in the general 
population. A diagnosis of diabetes at evaluation 
should preclude donation,22 and our data support 
the finding of a reduction in the absolute preva-
lence, although not the relative prevalence, of dia-
betes among black and Hispanic donors, prob-
ably as a result of donor-selection practices.
We observed that black and Hispanic donors 
had approximately twice the risk of chronic kid-
ney disease as white donors. In NHANES, the 
prevalence of chronic kidney disease was also 
twice as high among black respondents as among 
white respondents and tended to be higher 
among Hispanic respondents than among white 
respondents. Similarly, the 2008 U.S. Renal Data 
System registry reported that the national inci-
dence of end-stage renal disease among black 
persons was 3.7 times that among white persons, 
and end-stage renal disease among Hispanic 
persons was 1.5 times that among non-Hispanic 
white persons.32 Recent queries of registrations 
of kidney-transplant candidates showed that al-
though 12% of living kidney donors during the 
period from 1996 through 2007 were black, 
black donors represented 43% of 148 previous 
donors who were subsequently listed for kidney 
transplantation.33,34 Our data also suggest that 
nonwhite donors have an increased frequency of 
end-stage renal disease, although the number of 
such events was low. We did not detect signifi-
cant race-related differences in cardiovascular 
diagnoses.
Although we found evidence of socioeconomic 
Table 3. Estimated Prevalence of Hypertension and Diabetes among Living Donors 5 Years after Nephrectomy, as Compared  
with the General Population, According to Subgroup.
Age at Evaluation, Sex,  
and Race or Ethnic Group* Hypertension Diabetes
Living Donors† NHANES‡ Living Donors† NHANES‡
percent (95% confidence interval)
40 Yr
Female
Non-Hispanic white 13.9 (11.5–16.2) 16.4 (13.3–19.9) 3.5 (2.2–4.8) 3.4 (1.8–6.3)
Hispanic 18.4 (13.4–23.1) 10.4 (8.5–12.7) 5.7 (2.6–8.7) 7.5 (6.0–9.3)
Non-Hispanic black 20.3 (15.8–24.5) 24.0 (21.8–26.3) 5.2 (2.7–7.7)  8.6 (7.2–10.2)
Male
Non-Hispanic white 15.6 (12.9–18.1) 15.5 (12.8–18.5) 3.2 (2.0–4.4) 3.3 (1.7–6.0)
Hispanic 20.6 (14.9–25.8) 9.8 (7.9–12.0) 5.2 (2.3–8.1) 7.2 (5.6–9.3)
Non-Hispanic black 22.7 (17.7–27.4) 24.4 (22.3–26.7) 4.8 (2.4–7.1)  8.5 (6.7–10.6)
55 Yr
Female
Non-Hispanic white 31.5 (27.1–35.7) 32.5 (28.4–36.8) 6.7 (4.4–9.0) 6.9 (5.5–8.7)
Hispanic 40.2 (30.5–48.6) 21.6 (18.1–25.6) 10.8 (4.8–16.4)  14.5 (11.8–17.7)
Non-Hispanic black 43.7 (35.3–51.1) 42.8 (40.0–45.8) 10.0 (5.2–14.6)  16.5 (14.4–18.9)
Male
Non-Hispanic white 34.9 (29.8–39.6) 31.0 (27.7–36.8) 6.2 (3.8–8.4) 6.6 (5.4–8.2)
Hispanic 44.2 (33.3–53.3) 20.5 (16.9–24.5)  9.9 (4.2–15.4)  14.5 (11.8–17.7)
Non-Hispanic black 47.9 (38.5–55.8) 44.3 (41.3–47.5)  9.2 (4.5–13.7)  16.4 (13.3–19.9)
* Values are for living kidney donors who were evaluated 5 years after nephrectomy.
† Diagnoses after kidney donation were ascertained from diagnosis codes on billing claims.
‡ Diagnoses in the National Health and Nutrition Examination Survey (NHANES) were defined by respondents’ reports of diagnoses on the 
basis of clinical encounters.
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disadvantage for nonwhite donors, the donor’s 
socioeconomic status did not correlate with the 
studied medical diagnoses. Since all donors had 
private health insurance during the observation 
period, it may be that possession of insurance 
attenuated health disparities that were based on 
socioeconomic status. In addition, our socioeco-
nomic measure may have lacked precision, since 
we used neighborhood socioeconomic status as 
a surrogate for individual status. The exclusion of 
uninsured donors may have underestimated med-
ical complications in nonwhite donors,35 since a 
lack of health insurance is more common among 
nonwhite donors than among white donors.36,37
Our study has inherent limitations, given the 
available data and sampling approach. Reasons 
for entry into and exit from the insurance plan 
are not available, and disenrollment related to 
events such as health status cannot be identified. 
Outcome measures that were available in the 
administrative data differed from those in the 
NHANES data. Billing claims have been shown 
to provide sensitive measures of diagnoses of 
diabetes and cardiovascular disease in other pop-
ulations15,19 but probably underrepresent the bur-
den of kidney dysfunction, as compared with 
laboratory-based measures.17
On the basis of claims data that may be left-
censored for the absence of insurance benefits 
within the available data, we were unable to dis-
tinguish incident diagnoses definitively. The sub-
analysis of the period during which the OPTN 
collected baseline data on hypertension suggests 
that some centers have allowed more potential 
white donors with elevated blood pressure at 
evaluation to proceed with donation, as compared 
with those of another race or ethnic group. This 
finding is consistent with limited data describ-
ing white race as a low-risk criterion for hyper-
tension among potential donors.23 Yet despite the 
apparent exclusion of potential black kidney do-
nors with reported hypertension at evaluation, 
black donors had an increased rate of hyperten-
sion after nephrectomy, as compared with white 
donors. It is possible that the evaluation and 
reporting of normal blood pressure from the 
donor-candidacy evaluation to OPTN vary across 
centers. The study data also lacked baseline in-
formation on body-mass index.
The stringency of living-donor selection has 
inherent tensions with the goal of increasing the 
organ supply. Black patients with end-stage re-
nal disease have decreased access to transplan-
tation, including living-donor allografts, as com-
pared with white patients.38,39 As compared with 
white candidates for kidney transplantation, black 
candidates are less likely to identify potential 
living donors, and their potential living donors 
are less likely to donate for reasons including 
medical exclusion.40 Despite these exclusions 
from donation and the demonstrated benefit of 
selection for kidney donation in reducing the 
absolute risk of some health complications, such 
as diabetes, our data show that as in the general 
population, black kidney donors remain at in-
creased relative risk for hypertension, diabetes, 
and chronic kidney disease, as compared with 
white donors. Race and ethnic group should not 
be used to discourage donor evaluation, but these 
data may increase awareness of variation in long-
term outcomes among living donors and of the 
need for longer in-depth follow-up of demo-
graphically diverse living donors.
The interpretation and reporting of these data are the respon-
sibility of the authors and do not necessarily reflect the official 
policy of the OPTN, the Department of Defense, or the National 
Institutes of Health.
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Table 4. Variation in Neighborhood Socioeconomic Status Scores among 
3385 Living Kidney Donors at the Time of Nephrectomy, According to Race 
or Ethnic Group.*
Variable White Black Hispanic
Socioeconomic status index 49.1±5.3 43.9±6.0 43.7±7.6
Income score 24.8±8.5 19.6±7.1 21.2±8.1
Property-value score 14.5±10.3 11.1±6.0 14.5±10.2
Below federal poverty line (%) 9.1 16.4 16.4
Unemployed (%) 9.2 15.4 15.0
College graduate (%) 27.5 21.2 22.5
Education <12th grade (%) 15.7 22.9 26.8
Crowded household (%) 59.9 83.3 89.2
* Plus–minus values are means ±SD. Scores on the socioeconomic status index 
were computed for 3385 of 4650 donors (72.8%) for whom linked Census 
data were available. Scores for socioeconomic status, income, and property 
value are standardized to range from 0 to 100, with higher values indicating a 
higher level. Details about the calculation of these scores are provided in the 
Supplementary Appendix. P<0.001 for all comparisons of black and Hispanic 
donors with white donors, except for the comparison for property-value score 
between Hispanic donors and white donors.
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